MLYS catalyst calendar

Mineralys Therapeutics, Inc.

Upcoming catalysts
1
Cash runway
10.5 months
Cash & investments
$138M
Phase 3 programs
2

Mineralys Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.

Cash runway is approximately 10.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 11, 2026 est. Next quarterly earnings (projected) Earnings —

Track MLYS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MLYS in the tracker

Recent history

DateEventTypePhase
August 11, 2026 Quarterly results filed (8-K) Earnings —
June 3, 2026 8-K filed: Material agreement Corporate —
June 3, 2026 8-K filed: Other event Filing —
May 6, 2026 Quarterly results filed (8-K) Earnings —
March 12, 2026 Quarterly results filed (8-K) Earnings —
March 9, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 6, 2026 8-K filed: Reg FD disclosure, Other event Filing —
December 30, 2025 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Trial Milestone Phase 3
December 17, 2025 A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension Trial Milestone Phase 2
November 10, 2025 Quarterly results filed (8-K) Earnings —
September 3, 2025 8-K filed: Other event Filing —
September 2, 2025 8-K filed: Other event Filing —
August 12, 2025 Quarterly results filed (8-K) Earnings —
June 17, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 12, 2025 Quarterly results filed (8-K) Earnings —
February 27, 2025 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria Trial Milestone Phase 2
January 15, 2025 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen Trial Milestone Phase 2
December 10, 2024 Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension Trial Milestone Phase 3
September 7, 2022 Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.